nivolumab
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
October 30, 2023Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …
Immune system influences immunotherapy effectiveness, research shows
April 3, 2017Research and Development, Sales and Marketing immunotherapy, nivolumab, opdivo
Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune …
Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial
September 1, 2016Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq
Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …
Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials
April 19, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
FDA grants Opdivo breakthrough status for kidney cancer
September 18, 2015Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma
The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
BMS to trial Opdivo in solid tumours
July 30, 2015Research and Development BMS, Bristol-Myers Squibb, Kyowa Hakko Kirin, Poteligeo, mogamulizumab, nivolumab, opdivo, solid tumours
Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
BMS Opdivo trial scores early goal
January 14, 2015Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo
A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …
World’s first anti-PD-1 therapy approved
July 8, 2014Research and Development, Sales and Marketing BMS, Cancer, melanoma, nivolumab, ono, opdivo
Ono Pharmaceutical has been given the world’s first licence for a new type of cancer treatment on which many researchers’ …
New BMS cancer treatment shines
June 25, 2014Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab
Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …
